Calamos Advisors LLC Reduces Holdings in GeneDx Holdings Corp. (NASDAQ:WGS)

Calamos Advisors LLC trimmed its position in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 30.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 59,527 shares of the company's stock after selling 25,475 shares during the period. Calamos Advisors LLC owned approximately 0.22% of GeneDx worth $4,575,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. MCF Advisors LLC lifted its position in GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after purchasing an additional 182 shares during the period. CWM LLC acquired a new position in GeneDx during the third quarter valued at $89,000. Evolution Wealth Advisors LLC acquired a new position in GeneDx during the fourth quarter valued at $202,000. PFG Investments LLC acquired a new position in GeneDx during the fourth quarter valued at $252,000. Finally, SG Americas Securities LLC acquired a new position in GeneDx during the third quarter valued at $198,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, major shareholder School Of Medicine At Mo Icahn sold 126,782 shares of the company's stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $70.78, for a total value of $8,973,629.96. Following the transaction, the insider now directly owns 2,719,692 shares in the company, valued at approximately $192,499,799.76. This represents a 4.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Katherine Stueland sold 1,657 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36. Following the sale, the chief executive officer now directly owns 3,937 shares in the company, valued at approximately $308,975.76. The trade was a 29.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 363,669 shares of company stock worth $28,061,081. 27.30% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have weighed in on WGS shares. TD Cowen lifted their price objective on shares of GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a report on Tuesday, January 7th. Wells Fargo & Company lifted their price objective on shares of GeneDx from $34.00 to $75.00 and gave the company an "equal weight" rating in a report on Wednesday, October 30th. Craig Hallum lifted their price objective on shares of GeneDx from $70.00 to $95.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Finally, The Goldman Sachs Group boosted their target price on shares of GeneDx from $54.00 to $70.00 and gave the stock a "neutral" rating in a research note on Wednesday, October 30th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $70.67.

GeneDx Price Performance

Shares of WGS stock traded down $2.63 on Friday, reaching $59.54. 1,276,246 shares of the company were exchanged, compared to its average volume of 1,019,063. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -19.14 and a beta of 2.01. The business has a 50-day moving average price of $76.94 and a 200 day moving average price of $59.32. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. GeneDx Holdings Corp. has a 1 year low of $3.68 and a 1 year high of $98.87.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.